Research progress on botulinum toxin type A in the treatment of Raynaud's phenomenon

doi:10.16352/j.issn.1001-6325.2022.10.1611

Abstract

Abstract: Raynaud's phenomenon is a common vasospasm response, and current medical therapies and surgical treatments show limited clinical effects. Botulinum toxin type A has certain effectiveness and safety in treating Raynaud's phenomenon. It can relax blood vessels, relieve pain, and has a good long-term effect. Its side effects are mild, such as pain at the injection site, bruises, or transient muscle weakness. In recent years, some research has broadened the scope of application of the treatment and determined more effective injection doses and injection methods to reduce the side effects. More large-sample randomized double-blind controlled trials and animal experiments are needed to provide information for explaining the treatment mechanisms and illstrating the efficacy.

Key words: Raynaud's phenomenon, botulinum toxin type A

CLC Number:

R816.95

WANG Yuan-zhuo, ZHENG Qing-yue, ZHANG Han-lin, TANG Ke-yun, FANG Rou-yu, SUN Qiu-ning. Research progress on botulinum toxin type A in the treatment of Raynaud's phenomenon[J]. Basic & Clinical Medicine, 2022, 42(10): 1611-1615.

References 25

[1]	Sycha T, Graninger M, Auff E, et al. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study[J]. Eur J Clin Invest,2004,34:312-313.
[2]	Herrick AL, Wigley FM. Raynaud's phenomenon[J]. Best Pract Res Clin Rheumatol,2020,101474. doi: 10.1016/j.berh.2019.101474.
[3]	Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines-the diagnosis and management of Raynaud's phenomenon[J]. Vasa,2017,46:413-423.
[4]	Fábián B, Fábián AK, Bugán A, et al. Comparison of mental and physical health between patients with primary and secondary Raynaud's phenomenon category: article[J]. J Psychosom Res,2019,116:6-9.
[5]	陈彦强,王永平,杨同群,等. 肉毒毒素A对大鼠慢性神经源性疼痛中P物质和炎性反应的影响[J]. 基础医学与临床, 2016, 36: 1517-1524.
[6]	Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon[J]. J Hand Surg Am,2010,35:2085-2092.
[7]	Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma[J]. J Hand Surg Eur Vol,2014,39:876-880.
[8]	Jenkins SN, Neyman KM, Veledar E, et al. A pilot study evaluating the efficacy of botulinum toxin A in the treat-ment of Raynaud phenomenon[J]. J Am Acad Dermatol,2013,69:834-835.
[9]	Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study[J]. J Dermatol,2016,43:56-62.
[10]	Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-Blind, placebo-controlled clinical trial[J]. Arthritis Rheumatol,2017,69:1661-1669.
[11]	Berk-Krauss J, Christman MP, Franks A, et al. Botuli-num toxin for treatment of Raynaud phenomenon in CREST syndrome[J]. Dermatol Online J,2018,24:13030-13031.
[12]	Dhaliwal K, Griffin M, Denton CP, et al. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes[J]. BMJ Case Rep,2018. doi: 10.1136/bcr-2017-219348.
[13]	Garrido-Rios AA, Gonzalez-Olivares M, Navarro-Vidal B, et al. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin[J]. Clin Exp Dermatol,2018,43:503-505.
[14]	Asad U, Austin B, Tarbox M, et al. Botulinum toxin in the long-term treatment of refractory Raynaud's phenome-non[J]. J Drugs Dermatol,2019,18:943-945.
[15]	Winter AR, Camargo Macias K, Kim S, et al. The effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon: a case series[J]. Cureus,2020,12:e8235. doi: 10.7759/cureus.8235.
[16]	Boukovalas S, Mays AC, Selber JC. Botulinum toxin injection for lower face and oral cavity Raynaud phenomenon after mandibulectomy, free fibula reconstruction, and radiation therapy[J]. Ann Plast Surg,2019,82:53-54.
[17]	Cho KS, Yoon JS, Ahn HC. Botulinum A toxin injection as an adjuvant wintering therapy in patients with Raynaud's syndrome[J]. Arch Hand Microsurg,2019,24:210-217.
[18]	Quintana Castanedo L, Feito Rodríguez M, Nieto Rodríguez D, et al. Botulinum toxin A treatment for primary and secondary Raynaud's phenomenon in teenagers[J]. Dermatol Surg,2021,47:61-64.
[19]	Dhaliwal K, Griffin MF, Salinas S, et al. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series[J]. Clin Rheumatol,2019,38:3669-3676.
[20]	Quintana-Castanedo L, Feito-Rodríguez M, De Lucas-Laguna R. Interdigital injection of botulinum toxin for patients with Raynaud's phenomenon[J]. J Am Acad Dermatol,2019:S0190-9622:33208-33216.
[21]	Lobb DC, Pierce J, Perry M, et al. The use of ultrasound guidance for the treatment of raynaud disease of the hand with botulinum toxin[J]. Ann Plast Surg,2020,84:S386-S388.
[22]	Medina S, Gómez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study[J]. Eur J Rheumatol,2018,5:224-229.
[23]	Cartee TV, Monheit GD. An overview of botulinum toxins: past, present, and future[J]. Clin Plast Surg,2011,38:409-426.
[24]	Nagarajan M, McArthur P. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience[J]. Rheumatol Int,2020. doi: 10.1007/s00296-020-04606-4.
[25]	Eickhoff JC, Smith JK, Landau ME, et al. Iatrogenic thenar eminence atrophy after botox a injection for secondary raynaud phenomenon[J]. J Clin Rheumatol,2016,22:396-397.